Kidney transplantation admissions in the Medicare fee-for-service population
Download infographicDownload full report
Chronic kidney disease (CKD) poses a substantial health burden globally, presenting a high economic cost to health systems and increasing the risk of cardiovascular morbidity, premature mortality, and decreased quality of life. The Centers for Disease Control and Prevention estimates that 36 million adults--14% of the U.S. adult population--have CKD. Sanofi U.S. recently commissioned Milliman to investigate the economic implications of kidney transplants on the nation’s hospitals. In the report, we summarize our findings, including:
- Clinically relevant characteristics with hospital resource implications and hospital charges
- Estimated hospital internal costs
- Medicare fee-for-service (FFS) allowed costs for kidney transplant admissions
This report was commissioned by Sanofi U.S.
About the Author(s)
Dagny Grillis
Kidney transplantation admissions in the Medicare fee-for-service population
As part of an analysis for Sanofi U.S., we examine the economic implications of kidney transplants, including hospital expense and Medicare allowed costs.